-

Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development. With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony brings extensive knowledge and expertise to Seek Labs where she will spearhead the pharmaceutical research division, leading strategic initiatives to advance Seek Labs’ innovation in novel gene therapies.

An immunologist and cell biologist by training, O’Mahony has extensive experience leading scientific teams and assay operations in drug discovery. She has led academic research efforts, CRO-based phenotypic screening services, and drug discovery efforts in biotech. O’Mahony has served as a subject-matter expert in disease biology (immunology, inflammation, immune-oncology, and fibrosis), has published several peer-reviewed articles, and presented at international conferences.

"We are delighted to welcome Alison O’Mahony to Seek Labs as our new Vice President of Pharmaceutical Development," said Jared Bauer, CEO. "Her proven track record in research and leadership will be instrumental in accelerating Seek Labs’ efforts to bring our novel gene therapies to patients, ultimately improving patient outcomes worldwide. We are confident her expertise in both pharmaceutical innovation and building successful teams, as well as her commitment to the community and passion for healthcare, will play a pivotal role in driving our mission to impact global health."

O’Mahony has served in scientific leadership roles at Recursion, Eurofins and DiscoverX. She earned a BSc in Biochemistry and Microbiology from University College Cork from where she went on to earn a PhD in Immunology.

O’Mahony expressed her enthusiasm to join Seek Labs and lead pharmaceutical development: "I am looking forward to collaborating with talented colleagues and leveraging our collective expertise to advance the company’s novel research towards meaningful treatments. I am passionate about the potential for the science, technology, and innovation at Seek Labs to deliver superior and accessible therapeutic strategies that benefit patients."

O’Mahony is deeply committed to building and serving the wider scientific community. She is passionate about helping her community realize the full potential of motivated individuals to drive innovation, improve healthcare outcomes, expand markets, and address health disparities. She is a founding member of the BioHive Women in Technology and STEM (WITS) chapter, which focuses on supporting and promoting women in Utah’s STEM fields. She also serves on professional boards including Talent Ready Utah, Breakthrough Cancer Research, and the Inflammation Research Association.

About Seek Labs

Seek Labs is a company united by a vision to advance scientific discovery and universal solutions. Seek Labs strives to innovate healthcare solutions that bridge gaps between patients, providers, and treatments. Seek Labs is united by the passion of our founders and their shared beliefs that healthcare solutions should empower individuals and serve their specific needs. Today—after years of experimentation, failure, and breakthrough— Seek Labs is developing new solutions for point-of-care diagnostics and pharmaceutical technologies that have the potential to revolutionize the detection and treatment of diseases.

Seek Labs is headquartered in Salt Lake City, Utah. Seek Labs is a proud member of the BioHive, a collective representing the life science and healthcare innovation ecosystem in Utah. BioHive is dedicated to all the ways our work can positively impact the lives of our community, our teams, and patients.

Contacts

Bridget Baldwin
Director of Communications, Seek Labs
bridget@seeklabs.com

Seek Labs


Release Versions

Contacts

Bridget Baldwin
Director of Communications, Seek Labs
bridget@seeklabs.com

Social Media Profiles
More News From Seek Labs

Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotechnology company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the publication of a peer-reviewed paper in Viruses (MDPI), revealing the first successful use of a CRISPR-based therapeutic to treat African Swine Fever Virus (ASFV) in pigs. The findings demonstrate the company’s proprietary CRISPR-based therapeutic successfully reduced viremia, enabling rec...

Seek Labs Expands Global Disease Atlas with Mapping of Hemorrhagic Fever Viruses through BioSeeker™

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery programmable therapeutics, and point-of-care diagnostics, today announced an expansion of its Global Disease Atlas™ to include multiple hemorrhagic fever viruses. BioSeeker™, the company’s AI-powered discovery engine, has completed comprehensive genomic mapping across a suite of high-priority hemorrhagic fever viruses (HFV), which include Ebola virus, Marburg virus, Lassa...

Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced progress toward developing the world’s first pan-orthopoxvirus therapeutic, a breakthrough with significant implications for global health security. Orthopoxviruses are part of a group of double-stranded DNA viruses in the Poxviridae family that infect mammals, which include subtypes like human smal...
Back to Newsroom